Current Management of Castration-Resistant Prostate Cancer (CRPC)

Dear Colleagues,

In recent years, the treatment of castration-resistant prostate cancer has witnessed dramatic advances. Currently, the inhibition of androgen receptor signaling, chemotherapy, and radioligand therapies in various sequences are the mainstay of therapy. However, sooner or later, primary or secondary resistance against any given therapy inevitably occurs. Reasons for this include sustained proliferative androgen receptor signaling, activating point mutations of the androgen receptor, alternative splicing of the androgen receptor, cell cycle activation, evading apoptosis, inducing angiogenesis, activating invasion and metastasis, defective DNA-repair machinery, evasion of immune control, and many more. All of these occur in the context of chronic inflammation and genomic instability. Castration-resistant prostate cancer is still uncurable, and accounts for nearly all prostate cancer-related deaths. Understanding the genetic and biological mechanisms leading to therapy resistance and sustaining progression is crucial to achieving further advances in the sequencing of available drugs and management of castration-resistant prostate cancer in general. Any experimental and clinical work potentially relevant to this Special Issue will be carefully considered for inclusion.

Prof. Dr. Martin Bögemann
Prof. Dr. Tilman Todenhöfer
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.